Design, synthesis and biological activities of pyrrole-3-carboxamide derivatives as EZH2 (enhancer of zeste homologue 2) inhibitors and anticancer agents

被引:13
作者
Zhou, Qifan [1 ]
Jia, Lina [2 ]
Du, Fangyu [1 ]
Dong, Xiaoyu [2 ]
Sun, Wanyu [2 ]
Wang, Lihui [2 ]
Chen, Guoliang [1 ]
机构
[1] Shenyang Pharmaceut Univ, Key Lab Struct Based Drugs Design & Discovery, Minist Educ, Sch Pharmaceut Engn, 103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China
[2] Shenyang Pharmaceut Univ, Dept Pharmacol, 103 Wenhua Rd, Shenyang 110016, Liaoning, Peoples R China
基金
中国国家自然科学基金;
关键词
HISTONE METHYLTRANSFERASE EZH2; CANCER; IDENTIFICATION; OPTIMIZATION; DISCOVERY; RECEPTOR; KETONES; POTENT;
D O I
10.1039/c9nj04713a
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Zeste enhancer homolog 2 (EZH2) is highly expressed in various malignant tumors, which could silence tumor suppressor genes via trimethylation of H3K27. Herein was first reported a novel series of pyrrole-3-carboxamide derivatives carrying a pyridone fragment as EZH2 inhibitors. By combining computational modeling, in vitro cellular assays and further rational structure-activity relationship exploration and optimization, compound DM-01 showed powerful inhibition towards EZH2. DM-01 was found to have significant ability to reduce the cellular H3K27me3 level in K562 cells in the Western blot test. Meanwhile, our data showed that knockdown EZH2 in A549 cells resulted in a decrease of cell sensitivity to DM-01 at 50 and 100 mu M. DM-01 could also increase the transcription expression of DIRAS3 in a dose-dependent manner, a tumor suppressor in the downstream of EZH2, suggesting it was worth investigating further as a lead compound.
引用
收藏
页码:2247 / 2255
页数:9
相关论文
共 31 条
  • [1] EZH2 Promotes Malignant Phenotypes and Is a Predictor of Oral Cancer Development in Patients with Oral Leukoplakia
    Cao, Wei
    Younis, Rania H.
    Li, Jiang
    Chen, Haiyan
    Xia, Ronghui
    Mao, Li
    Chen, Wantao
    Ren, Hening
    [J]. CANCER PREVENTION RESEARCH, 2011, 4 (11) : 1816 - 1824
  • [2] EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling
    Chang, Chun-Ju
    Yang, Jer-Yen
    Xia, Weiya
    Chen, Chun-Te
    Xie, Xiaoming
    Chao, Chi-Hong
    Woodward, Wendy A.
    Hsu, Jung-Mao
    Hortobagyi, Gabriel N.
    Hung, Mien-Chie
    [J]. CANCER CELL, 2011, 19 (01) : 86 - 100
  • [3] Molecular field technology applied to virtual screening and finding the bioactive conformation
    Cheeseright, Tim
    Mackey, Mark
    Rose, Sally
    Vinter, Andy
    [J]. EXPERT OPINION ON DRUG DISCOVERY, 2007, 2 (01) : 131 - 144
  • [4] Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
    Gardner, Eric E.
    Lok, Benjamin H.
    Schneeberger, Valentina E.
    Desmeules, Patrice
    Miles, Linde A.
    Arnold, Paige K.
    Ni, Andy
    Khodos, Inna
    de Stanchina, Elisa
    Thuyen Nguyen
    Sage, Julien
    Campbell, John E.
    Ribich, Scott
    Rekhtman, Natasha
    Dowlati, Afshin
    Massion, Pierre P.
    Rudin, Charles M.
    Poirier, John T.
    [J]. CANCER CELL, 2017, 31 (02) : 286 - 299
  • [5] Hallmarks of Cancer: The Next Generation
    Hanahan, Douglas
    Weinberg, Robert A.
    [J]. CELL, 2011, 144 (05) : 646 - 674
  • [6] EZH2: An Epigenetic Gatekeeper Promoting Lymphomagenesis
    Heyn, Holger
    Esteller, Manel
    [J]. CANCER CELL, 2013, 23 (05) : 563 - 565
  • [7] Recent progress in developing selective inhibitors of protein methyltransferases
    Kaniskan, H. Umit
    Jin, Jian
    [J]. CURRENT OPINION IN CHEMICAL BIOLOGY, 2017, 39 : 100 - 108
  • [8] Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
    Knutson, Sarah K.
    Kawano, Satoshi
    Minoshima, Yukinori
    Warholic, Natalie M.
    Huang, Kuan-Chun
    Xiao, Yonghong
    Kadowaki, Tadashi
    Uesugi, Mai
    Kuznetsov, Galina
    Kumar, Namita
    Wigle, Tim J.
    Klaus, Christine R.
    Allain, Christina J.
    Raimondi, Alejandra
    Waters, Nigel J.
    Smith, Jesse J.
    Porter-Scott, Margaret
    Chesworth, Richard
    Moyer, Mikel P.
    Copeland, Robert A.
    Richon, Victoria M.
    Uenaka, Toshimitsu
    Pollock, Roy M.
    Kuntz, Kevin W.
    Yokoi, Akira
    Keilhack, Heike
    [J]. MOLECULAR CANCER THERAPEUTICS, 2014, 13 (04) : 842 - 854
  • [9] Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
    Kung, Pei-Pei
    Bingham, Patrick
    Brooun, Alexei
    Collins, Michael
    Deng, Ya-Li
    Dinh, Dac
    Fan, Connie
    Gajiwala, Ketan S.
    Grantner, Rita
    Gukasyan, Hovhannes J.
    Hu, Wenyue
    Huang, Buwen
    Kania, Robert
    Kephart, Susan E.
    Krivacic, Cody
    Kumpf, Robert A.
    Khamphavong, Penney
    Kraus, Manfred
    Liu, Wei
    Maegley, Karen A.
    Nguyen, Lisa
    Ren, Shijian
    Richter, Dan
    Rollins, Robert A.
    Sach, Neal
    Sharma, Shikhar
    Sherrill, John
    Spangler, Jillian
    Stewart, Albert E.
    Sutton, Scott
    Uryu, Sean
    Verhelle, Dominique
    Wang, Hui
    Wang, Shuiwang
    Wythes, Martin
    Xin, Shuibo
    Yamazaki, Shinji
    Zhu, Huichun
    Zhu, JinJiang
    Zehnder, Luke
    Edwards, Martin
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2018, 61 (03) : 650 - 665
  • [10] The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat
    Kuntz, Kevin W.
    Campbell, John E.
    Keilhack, Heike
    Pollock, Roy M.
    Knutson, Sarah K.
    Porter-Scott, Margaret
    Richon, Victoria M.
    Sneeringer, Chris J.
    Wigle, Tim J.
    Allain, Christina J.
    Majer, Christina R.
    Moyer, Mikel P.
    Copeland, Robert A.
    Chesworth, Richard
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (04) : 1556 - 1564